Zelira Therapeutics: Confirms ZTL-103 is safe and well-tolerated
- Zelira Therapeutics has confirmed its phase one dose-escalation trial of ZTL-103 has successfully met clinical endpoints for safety and efficacy
- Then the cannabis formulation given to chronic pain patients who already taking high doses of opioids
- ZTL-103 proved to well-tolerated with no serious adverse events
- Notably, patients reported an improvement with pain, stress, anxiety and depression
- Zelira will also use the data to expand its portfolio and inform a future trial which will treat retired athletes with chronic pain
- Company shares are up 3.64 per cent and are trading for 5.7 cents each
